ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Glenn Short, PhD, Vice President of Early Development, at ATAI Life Sciences ATAI was a guest speaker at Benzinga’s Psychedelic Capital Conference (PCC). 

ATAI is a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. 

Watch the full interview here. 

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Photo by Marcel StrauB on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Penny StocksPsychedelicsSmall CapMarketsATAI Life SciencesBenzinga Psychedelic Capital ConferencePartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!